What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision
This clinical-stage biotech focused on hypertension therapies reported a notable insider sale amid strong one-year stock performance.
What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision
Overview
David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics (NASDAQ:MLYS), reported the direct sale of 14,474 shares of Common Stock for a total transaction value of approximately $350,000, according to a SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($24.19); post-transaction value based on June 17, 2026 market close (calculated using actual closing price).
Details
* 1-year performance calculated using June 17, 2026 as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
